When the European Commission decided to approve Ceplene last October, Epicept (EPCT) looked to be as safe an investment as any since the only thing that stood in the way of Epicept and a revenue stream was the search for a marketing partner.

Now, seven months later, shares of Epicept trade for a mere sixty cents on minuscule volume and investors are beginning to wonder if EPCT is still worth the wait.